Patent application number | Description | Published |
20090137633 | Stable pharmaceutical composition of rabeprazole - The present invention relates to a method of preparing a stable pharmaceutical composition of rabeprazole. The preparation may be used as an injectable dosage form in the treatment of severe gastric ulcers. | 05-28-2009 |
20090177008 | NOVEL PROCESS FOR SYNTHESIS OF ITOPRIDE AND ITS NOVEL INTERMEDIATE N-(4-HYDROXYBENZYL)- 3,4-DIMETHOXYBENZAMIDE - The present invention relates to a novel and improved process for the preparation of N-[4-[2-(dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide—known as Itopride, via a novel intermediate N-(4˜hydroxybenzyl)-3,4-dimethoxybenzamide. | 07-09-2009 |
20100062026 | POLY TLR ANTAGONIST - w or its components are found to have poly TLR antagonistic activity to induced TLRs by varieties of TLR ligands. The induced TLR against which inhibitory effect is seen includes TLR 3, 4, 5, 6, 7, 8, 9. They also display antagonistic activities to effects of TLR ligands. They are also useful in management of diseases wherein TLRs are over expressed, like sepsis, multiple sclerosis, optic neuritis, Chronic obstructive pulmonary diseases multiple myeloma etc. | 03-11-2010 |
20100104536 | P38 INHIBITORS - The invention relates to novel p38 MAPK inhibitor which involves | 04-29-2010 |
20100113802 | PROCESS FOR PREPARING AMORPHOUS ATORVASTATIN HEMI CALCIUM SALT AND ITS ITERMEDIATE - The invention relates to the HMG-CoA reductase inhibitor in particular to Atorvastatin Hemi-calcium. The present invention is directed to novel processes for preparing amorphous form of Atorvastatin hemi calcium and their intermediate in high purity. | 05-06-2010 |
20100209394 | MITOGEN ACTIVATED PROTEIN KINASE MODULATOR - The present invention describes the method of modulating MAPK pathways. Further more the invention describes the use of Mycobacterium w for modulation of MAPK pathway intermediates for treatment of MAPK mediated conditions. | 08-19-2010 |
20110020440 | STABLE SOLUTIONS OF SPARINGLY SOLUBLE ACTIVES - The present invention relates to a stable pharmaceutical composition comprising soft gelatin capsules containing at least one sparingly soluble active drug (singly or in combination with sparingly soluble and/or soluble drugs) and a solvent system, wherein the solvent system comprises of solvent, co-solvent, solubilizer(s), surfactant, aqueous solution of alkali and crystal growth inhibitor. The present invention further relates to process for preparing a stable pharmaceutical composition of sparingly soluble active drug(s) in soft gelatin capsules. | 01-27-2011 |
20110182939 | Vaccine Adjuvants - The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response. | 07-28-2011 |
20110183919 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS - The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme. | 07-28-2011 |
20120014985 | Vaccine Adjuvants - The invention relates to a novel adjuvant | 01-19-2012 |
20120027849 | STABLE PHARMACEUTICAL COMPOSITION FOR ATHEROSCLEROSIS - The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent/s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from β-adrenergic receptor blocking agent, ACE inhibitor and diuretic. The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor. The pharmaceutical composition made as per present invention a) overcomes any drug-drug interactions, b) exhibits pharmacokinetic and pharmacodynamic profile of individual therapeutic agent, c) has minimal side effects. The invention provides multi-component composition (MCC) to increase adherences to therapy. The MCC as per present invention provides compositions that maintain activity of all active ingredients without significant increase in adverse event profile. The present invention further relates to a method of preparing the said pharmaceutical composition. | 02-02-2012 |
20120308605 | Pharmaceutical Composition of Killed Cells with Substantially Retained Immunogenicity - This invention discloses the process for lyophilisation of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting. Immunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy. | 12-06-2012 |
20120328574 | P38 INHIBITORS - The invention relates to novel p38 MAPK inhibitor which involves | 12-27-2012 |
20130137852 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF - The present invention relates to process for preparation of novel compounds which are acting as inhibitors of dipeptidyl peptidase-IV enzyme and is depicted by the structural formula as given below: Formula VI. Which are useful in the treatment or prevention of diseases in which the dipeptidylpeptidase-IV enzyme is involved, such as diabetes and particularly type-2 diabetes. | 05-30-2013 |
20130225689 | PHARMACEUTICAL COMPOSITIONS OF CURCUMIN - The present invention relates to stable liquid pharmaceutical compositions of curcumin or its pharmaceutically acceptable salts or its derivatives with higher curcumin concentration and improved bioavailability without the use of buffer and/or molecular aggregation inhibitor(s). In accordance with present invention the curcumin is in the solubilized form to make a stable liquid pharmaceutical composition. | 08-29-2013 |
20130295648 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER - The present invention relates to increase in survival of mammals suffering from desmocollin 3 expressing cancers. | 11-07-2013 |
20130310447 | PHARMACEUTICAL COMPOSITION OF TAXOIDS - The present invention relates to a stable oral pharmaceutical composition with improved solubility and bioavailability; comprising a taxoid, a solubilizer, a stabilizing agent, a surfactant(s), a solvent(s), and an oil wherein the concentration of taxoid is in the range of 0.1 to 10%. | 11-21-2013 |
20130330375 | Therapeutic Cancer Vaccine - The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same. | 12-12-2013 |
20140045771 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS - The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme. | 02-13-2014 |
20140294896 | CANCER ANTIGEN - Cancer cells when treated with cisplatin, paclitaxel, gemcitabine, | 10-02-2014 |